Sugi Predict

Sugi Predict / Compounds / SCHEMBL23329339

SCHEMBL23329339

SCHEMBL23329339

O[C@H]1CC[C@@H](N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 1/20 0.55
▸ SLC6A2 P23975 2/20 0.47
▸ SLC6A4 P31645 2/20 0.47
▸ SLC6A3 Q01959 1/20 0.44
▸ SLC18A3 Q16572 1/20 0.44
▸ KMT2A Q03164 5/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ GRIN2B Q13224 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ OPRM1 P35372 2/20 0.41
▸ OPRD1 P41143 2/20 0.41
▸ OPRK1 P41145 2/20 0.41
▸ ACKR3 P25106 1/20 0.40
▸ G6PC1 P35575 1/20 0.40
▸ CCR5 P51681 1/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ DPP7 Q9UHL4 1/20 0.40
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384230 1.00 YTHDC1 (0.55) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL384229 1.00 YTHDC1 (0.55) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL17685339 0.92 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL3376962 0.90 YTHDC1 (0.58) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL25111999 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL23329113 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL25341885 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL29182197 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL29182199 0.89 YTHDC1 (0.49) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3
SCHEMBL13017781 0.84 SLC6A2 (0.53) YTHDC1SLC6A2SLC6A4SLC6A3SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617799-B2 Pyrazolopyrimidinone compounds Orphagen Pharmaceuticals, Inc. (US) 2026-05-05 — — US disclosed
US-12514858-B2 CD38 inhibitors Astellas Engineered Small Molecules US, Incorporated (US) 2026-01-06 — — US disclosed
US-20240208982-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. 2024-06-27 — — US disclosed
EP-4313988-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2024-02-07 — — EP disclosed
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 — — US disclosed
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 — — US disclosed
US-20230312605-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-10-05 — — US disclosed
US-20230312605-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-10-05 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230158024-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-05-25 — — US disclosed
US-20230158024-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-05-25 — — US disclosed
EP-4169575-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS Sato Pharmaceutical Co., Ltd. (JP) 2023-04-26 — — EP disclosed
EP-4132919-A1 CD38 INHIBITORS Mitobridge, Inc. (US) 2023-02-15 — — EP disclosed
CN-115667259-A Condensed ring compounds for inhibiting H-PGDS 佐藤制药株式会社 2023-01-31 — — CN disclosed
US-20230025807-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-01-26 — — US disclosed
US-20230025807-A1 CD38 INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2023-01-26 — — US disclosed
WO-2022204481-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2022-09-29 — — WO disclosed
WO-2022204481-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2022-09-29 — — WO disclosed
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025807-A1 CD38 INHIBITORS CD38, GLS, IDH2 YTHDC1 2791/4885SLC6A2 513/4885SLC6A4 1662/4885
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 YTHDC1 1583/4885SLC6A2 4428/4885SLC6A4 3754/4885
US-20240208982-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS CYP2C19, CYP3A4, CYP2C9 YTHDC1 4623/4885SLC6A2 2583/4885SLC6A4 1396/4885
US-20230312605-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B YTHDC1 3132/4885SLC6A2 4374/4885SLC6A4 3433/4885
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS HPGDS, PTGS1, PTGIS YTHDC1 4322/4885SLC6A2 4442/4885SLC6A4 3602/4885
US-12617799-B2 Pyrazolopyrimidinone compounds CYP2B6, CBR1, CYP2D6 YTHDC1 3462/4885SLC6A2 3238/4885SLC6A4 2617/4885
US-20230158024-A1 CD38 INHIBITORS CD38, NQO1, NDUFAB1 YTHDC1 2285/4885SLC6A2 974/4885SLC6A4 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.